Novo Nordisk Cuts Wegovy Price in China Ahead of Patent Expiration Amid Growing Copycats

Novo Nordisk has lowered the cost of its obesity treatment Wegovy in China in anticipation of patent expiration and rising generic competitors. The price reduction aims to ease patient treatment burdens, as reported in regional drug procurement data. This move also reflects changes on major online marketplaces, allowing nationwide ordering after doctor consultations.

The adjustment is evident in the pricing displayed on the online platform operated by the large Chinese e-commerce firm JD.com. After an online check-up with a healthcare professional, individuals across China can submit purchases through digital channels.

The Danish pharmaceutical powerhouse Novo Nordisk has decreased the cost of its weight control medicine Wegovy in China. This step is taken while the company anticipates a likely influx of imitation products.

According to an email from a company representative, the reduction is designed to "ease the financial strain of treatment for patients and enhance their overall well-being."

Referencing procurement documents for medications in the southwestern Chinese areas of Yunnan and Sichuan, local outlet Yicai disclosed on Monday that the listed prices for the top two doses of Wegovy have been cut in half across multiple regions in China.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

In China, Novo Nordisk's protection on semaglutide—the key ingredient in widely used treatments Wegovy and Ozempic—is set to end in March, prompting local enterprises to introduce more affordable generic options.

Recently, a domestically developed slimming drug from Innovent Biologics Inc. received approval in China, heightening the global competition that pits Novo against strong opponent Eli Lilly & Co.

For those managing weight loss, health monitoring tools such as Shotlee can assist in tracking progress effectively.

Source Information

Originally published by cnbctv18.com.Read the original article →

Keep exploring

More on Wegovy

Articles covering Wegovy dosing, side effects, and clinical updates.

Health & Wellness

Ozempic Price Cut: Generic Semaglutide Arrives in Canadian Pharmacies

Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.

7 min read

Health & Wellness

Retatrutide Breaks Records: What Phase 3 TRIUMPH-1 Data Means

Eli Lilly's Retatrutide has shown remarkable weight loss potential in Phase 3 trials. We break down the TRIUMPH-1 results, safety data, and what patients can expect.

9 min read

Health & Wellness

GLP-1s, Hormones, and Weight Loss: What Women Need to Know

Many women starting GLP-1 therapies experience significant weight loss, only to find their menopausal symptoms—like hot flashes and sleep issues—intensify. This phenomenon is often overlooked because rapid fat loss directly interacts with the body's declining estrogen production, creating a complex hormonal shift that many prescribers are not trained to address.

6 min read

Same topic: Drug Pricing

All Drug Pricing articles →

Healthcare Policy

Supreme Court Ruling: Medicare Drug Price Negotiations Move Forward

In a significant victory for healthcare cost containment, the Supreme Court has allowed Medicare to proceed with negotiating drug prices. This decision upholds a key provision of the Inflation Reduction Act and could impact the cost of many prescription medications, including widely used GLP-1 agonists.

6 min read

GLP-1 Medications

Wegovy's New Subscription Saves Up to $1,200/Year – Not for Everyone

Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.

4 min read

GLP-1 Medications

GLP-1s Insurance Pricing Challenges: Q&A with Whitney Stidom

High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.

6 min read

More in Pharmaceuticals

Weight Management

GLP-1 Weight Loss Drugs: Eli Lilly's Next-Gen Therapies vs. Novo Nordisk

The race for dominance in the lucrative weight loss drug market is intensifying. While Novo Nordisk's Wegovy has been a pioneer, Eli Lilly is rapidly advancing its pipeline with next-generation therapies poised to challenge the status quo. This article delves into the science, clinical data, and market implications of these groundbreaking treatments.

6 min read